ANVS Annovis Bio, Inc.

NYSE
$1.31

Annovis Bio, Inc. (ANVS) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.30 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -28.4% since its last earnings release on August 14, 2026.

Annovis Bio Beat Consensus Estimates
Friday, August 14, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · 8:00 AM ET
Earnings Whisper
-
vs ($0.30)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.38

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Annovis Bio, Inc.

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.